Razelle Kurzrock, MD, is a world leader in precision medicine and immunotherapy. As a board-certified practicing medical oncologist and researcher, she is one of the most highly cited scientists globally per Clarivate (Web of Science). She oversees the development of a new Precision Medicine and Rare Cancers initiative and has assumed leadership of the cancer clinical trials enterprise at MCW.

Dr. Kurzrock is known for founding/chairing the largest Phase 1 clinical trials department in the world while at the MD Anderson Cancer Center. More recently, at the University of California, San Diego Moores Cancer Center, Dr. Kurzrock founded and directed the Center for Personalized Cancer Therapy and the Experimental Therapeutics Program and served as Chief of Hematology and Oncology.

Dr. Kurzrock has served as national/international principal investigator on more than 100 clinical trials and brought oversight to more than 500 early-phase trials, with many agents yielding FDA approvals. She is the author of more than >900 peer-reviewed articles on PubMed and holds a highly exceptional Hirsch index (h-index) score of 142, with more than 82,000 citations. Her strong record of competitive funding is comprised of ~$125 million in lifetime funding, including ~$50 million in NIH research support.

Dr. Kurzrock also serves as the Chair of the Early Therapeutics and Rare Cancer Committee (NCI SWOG) and as one of the PIs of the DART trial (national immunotherapy trial for rare cancers, opened at >1000 sites) as well as the PI of TRACK, the national precision genomics trial for rare cancers sponsored by the TargetCancer Foundation.